EA202190458A1 - Составы, содержащие дендример - Google Patents
Составы, содержащие дендримерInfo
- Publication number
- EA202190458A1 EA202190458A1 EA202190458A EA202190458A EA202190458A1 EA 202190458 A1 EA202190458 A1 EA 202190458A1 EA 202190458 A EA202190458 A EA 202190458A EA 202190458 A EA202190458 A EA 202190458A EA 202190458 A1 EA202190458 A1 EA 202190458A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- compositions containing
- dendreimer
- cancer
- formula
- treatment
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/595—Polyamides, e.g. nylon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
- C08G69/02—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids
- C08G69/08—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids derived from amino-carboxylic acids
- C08G69/10—Alpha-amino-carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G83/00—Macromolecular compounds not provided for in groups C08G2/00 - C08G81/00
- C08G83/002—Dendritic macromolecules
- C08G83/003—Dendrimers
- C08G83/004—After treatment of dendrimers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Polymers & Plastics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Раскрыты фармацевтические составы, содержащие лиофилизированное соединение формулы (I)или его фармацевтически приемлемую соль, и способы их применения для лечения рака.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862719319P | 2018-08-17 | 2018-08-17 | |
PCT/IB2019/056924 WO2020035815A1 (en) | 2018-08-17 | 2019-08-15 | Dendrimer formulations |
Publications (1)
Publication Number | Publication Date |
---|---|
EA202190458A1 true EA202190458A1 (ru) | 2021-09-28 |
Family
ID=68084891
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA202190458A EA202190458A1 (ru) | 2018-08-17 | 2019-08-15 | Составы, содержащие дендример |
Country Status (22)
Country | Link |
---|---|
US (1) | US20220273677A1 (ru) |
EP (1) | EP3837017A1 (ru) |
JP (1) | JP2021534172A (ru) |
KR (1) | KR20210046704A (ru) |
CN (1) | CN112543664A (ru) |
AR (1) | AR115983A1 (ru) |
AU (1) | AU2019322205C1 (ru) |
BR (1) | BR112021002586A2 (ru) |
CA (1) | CA3108648A1 (ru) |
CL (1) | CL2021000389A1 (ru) |
CO (1) | CO2021002980A2 (ru) |
CR (1) | CR20210086A (ru) |
DO (1) | DOP2021000028A (ru) |
EA (1) | EA202190458A1 (ru) |
IL (1) | IL280829B1 (ru) |
MX (1) | MX2021001831A (ru) |
PE (1) | PE20210861A1 (ru) |
PH (1) | PH12021550323A1 (ru) |
SG (1) | SG11202101394YA (ru) |
TW (1) | TW202021575A (ru) |
UY (1) | UY38337A (ru) |
WO (1) | WO2020035815A1 (ru) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JOP20190191A1 (ar) * | 2017-02-22 | 2019-08-08 | Astrazeneca Ab | وحدات شجرية علاجية |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1981512B1 (en) * | 2006-01-20 | 2022-11-02 | Starpharma Pty Limited | Modified macromolecule |
TWI535712B (zh) * | 2010-08-06 | 2016-06-01 | 阿斯特捷利康公司 | 化合物 |
PT2729179T (pt) * | 2011-06-06 | 2020-11-25 | Starpharma Pty Ltd | Macromoléculas |
US20160220689A1 (en) * | 2013-09-10 | 2016-08-04 | Starpharma Pty Ltd. | Macromolecules of dendrimer-platinum conjugates |
JOP20190191A1 (ar) * | 2017-02-22 | 2019-08-08 | Astrazeneca Ab | وحدات شجرية علاجية |
TWI831817B (zh) * | 2018-08-17 | 2024-02-11 | 瑞典商阿斯特捷利康公司 | 治療癌症之方法 |
-
2019
- 2019-08-08 TW TW108128355A patent/TW202021575A/zh unknown
- 2019-08-15 BR BR112021002586-3A patent/BR112021002586A2/pt unknown
- 2019-08-15 CN CN201980052937.4A patent/CN112543664A/zh active Pending
- 2019-08-15 PE PE2021000209A patent/PE20210861A1/es unknown
- 2019-08-15 EP EP19779577.6A patent/EP3837017A1/en active Pending
- 2019-08-15 MX MX2021001831A patent/MX2021001831A/es unknown
- 2019-08-15 CA CA3108648A patent/CA3108648A1/en active Pending
- 2019-08-15 AU AU2019322205A patent/AU2019322205C1/en active Active
- 2019-08-15 CR CR20210086A patent/CR20210086A/es unknown
- 2019-08-15 US US17/268,632 patent/US20220273677A1/en active Pending
- 2019-08-15 JP JP2021507807A patent/JP2021534172A/ja active Pending
- 2019-08-15 EA EA202190458A patent/EA202190458A1/ru unknown
- 2019-08-15 KR KR1020217007686A patent/KR20210046704A/ko unknown
- 2019-08-15 IL IL280829A patent/IL280829B1/en unknown
- 2019-08-15 WO PCT/IB2019/056924 patent/WO2020035815A1/en unknown
- 2019-08-15 SG SG11202101394YA patent/SG11202101394YA/en unknown
- 2019-08-16 UY UY0001038337A patent/UY38337A/es unknown
- 2019-08-16 AR ARP190102354A patent/AR115983A1/es unknown
-
2021
- 2021-02-15 CL CL2021000389A patent/CL2021000389A1/es unknown
- 2021-02-15 PH PH12021550323A patent/PH12021550323A1/en unknown
- 2021-02-17 DO DO2021000028A patent/DOP2021000028A/es unknown
- 2021-03-04 CO CONC2021/0002980A patent/CO2021002980A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
EP3837017A1 (en) | 2021-06-23 |
TW202021575A (zh) | 2020-06-16 |
PH12021550323A1 (en) | 2021-10-04 |
AR115983A1 (es) | 2021-03-17 |
CA3108648A1 (en) | 2020-02-20 |
KR20210046704A (ko) | 2021-04-28 |
BR112021002586A2 (pt) | 2021-05-04 |
SG11202101394YA (en) | 2021-03-30 |
CN112543664A (zh) | 2021-03-23 |
AU2019322205A1 (en) | 2021-04-08 |
CO2021002980A2 (es) | 2021-03-19 |
UY38337A (es) | 2020-02-28 |
CL2021000389A1 (es) | 2022-02-25 |
MX2021001831A (es) | 2021-04-28 |
PE20210861A1 (es) | 2021-05-18 |
IL280829B1 (en) | 2024-02-01 |
AU2019322205C1 (en) | 2023-09-07 |
US20220273677A1 (en) | 2022-09-01 |
JP2021534172A (ja) | 2021-12-09 |
WO2020035815A1 (en) | 2020-02-20 |
DOP2021000028A (es) | 2021-03-15 |
AU2019322205B2 (en) | 2023-03-16 |
IL280829A (en) | 2021-04-29 |
CR20210086A (es) | 2021-03-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12021500014A1 (en) | Fused ring compounds | |
EA201891494A1 (ru) | Гетероциклические соединения в качестве иммуномодуляторов | |
EA202090530A1 (ru) | Производные 1-бензил-2-имино-4-фенил-5-оксоимидазолидина как ингибиторы протеазы вич | |
BR112017003054A2 (pt) | compostos de aminopirimidinila como inibidores de jak | |
EA201790078A1 (ru) | Ингибиторы mnk и связанные с ними способы | |
EA201991884A3 (ru) | Ингибиторы g12c kras | |
EA202090688A1 (ru) | Бис-амидные соединения, активирующие саркомер, и варианты их применения | |
EA201891063A1 (ru) | Производные дигидроимидазопиразинона, применимые в лечении рака | |
MX2023002507A (es) | Inhibidores de cd73. | |
EA201991700A1 (ru) | Селективные ингибиторы jak1 | |
PH12021550825A1 (en) | Quinoline derivatives as alpha4beta7 integrin inhibitors | |
EA202193015A1 (ru) | Ингибиторы cdk | |
EA201991894A1 (ru) | ПИПЕРИДИН-ЗАМЕЩЕННЫЕ ИНГИБИТОРЫ Mnk И СВЯЗАННЫЕ С НИМИ СПОСОБЫ | |
EA202191519A1 (ru) | Модуляторы trex1 | |
NZ788133A (en) | Cd73 inhibitors | |
MX2021012105A (es) | Compuestos de pirrol. | |
MX2021012096A (es) | Compuestos de indenilo, composiciones farmaceuticas y usos medicos del mismo. | |
MX2021007247A (es) | Derivados de rapamicina. | |
EA202191548A1 (ru) | Ингибиторы плазменного калликреина человека | |
MX2020011756A (es) | Compuesto farmaceutico, sales del mismo, formulaciones del mismo y metodos para hacer y usar el mismo. | |
EA202191192A1 (ru) | Кристаллические соли ингибитора плазменного калликреина | |
EA202091112A1 (ru) | Сокристаллы, фармацевтические композиции на их основе и способы лечения, предусматривающие их применение | |
PH12021550452A1 (en) | Methods of treating mycobacterial infections using tetracycline compounds | |
MX2021009717A (es) | Sulfonamidas biciclicas. | |
EA202190458A1 (ru) | Составы, содержащие дендример |